Fosun to Bring Cutting-Edge Cancer Treatment to China
CAR T cell therapy is a type of adoptive cell transfer (ACT) treatment considered to be the “fifth pillar” of cancer treatment, along with drugs, surgery, chemotherapy and radiation. ACT is a form of immunotherapy that collects and uses patients’ own immune cells to treat their cancer. Photo: Visual China
Chinese pharmaceutical giant Shanghai Fosun Pharmaceutical Group Co. Ltd. will launch the cell therapy Yescarta in China, a new variant of a cutting-edge cancer treatment that received its first U.S. regulatory approval just four months ago.
A joint venture between Fosun and Kite Pharma Inc., the U.S. developer of lymphoma treatment Yescarta, has launched an institute in Shanghai to localize the technology and eventually introduce it to the China market, Fosun said in a statement Tuesday.
You've accessed an article available only to subscribers
Try 4 weeks for $0.99
SUBSCRIBE
Share this article
Open WeChat and scan the QR code
RELATED
MOST POPULAR
- 1Caixin View: China Feels Chill From Trouble in Turkey
- 285-Year-Old Petitioner, in Poor Health, Denied Parole
- 3In Depth: HNA Charts New Course Back to Airline Basics
- 4On Beijing’s Orders, Tsinghua May Give Up Control of Chipmaker Units
- 5Banned From Planes and Trains, Jia Yueting Hands Over U.S. Car Startup’s China Business
SPONSORED
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas